SB96 - Abortion-Inducing Drug Safety Act

• Requires physicians to conduct in-person examinations and document gestational age and intrauterine location before administering abortion-inducing drugs, with follow-up visit approximately 14 days after administration.

• Mandates physicians provide patients with the drug label, maintain signed contracts with backup physicians for handling complications, and report adverse events to the FDA and state health department within three days.

• Establishes that only licensed physicians may administer abortion-inducing drugs following FDA-approved protocols for mifepristone (three 200 mg tablets followed by two 200 mcg tablets of misoprostol through 49 days LMP).

• Creates Class A felony penalties for intentional, knowing, or reckless violations, with no criminal penalties against the pregnant woman; provides civil liability including malpractice damages, professional disciplinary action, and wrongful death recovery.

• Becomes effective 90 days from governor signing.